伴髓系恶性肿瘤的家族性血小板疾病患者的自然史研究
本研究于2019年1月至2021年12月纳入214名参与者,其中111名患者携带39种不同的RUNX1变异,来自45个无关家庭。患者表现为血小板减少、血小板聚集异常、致密颗粒减少及出血评分异常,19例发生血液系统恶性肿瘤,其中18例对初始治疗耐药或复发并转诊行干细胞移植。
要点
- 111例患者中70/77有血小板减少,18/18血小板聚集异常,28/55出血评分异常。
- 19/111例诊断为血液系统恶性肿瘤,其中18例对初始治疗耐药或复发并转诊移植。
- 非恶性骨髓中42/55例见巨核细胞发育异常,30/55成人及17/21儿童见细胞减少。
核心结论
- 结果强调多学科方法、早期恶性肿瘤检测及对遗传性疾病更广泛认识的重要性。
- 这项持续入组的纵向研究将对更多FPDMM患者进行基因分型和表型分析,可能增进对疾病发病机制和临床病程的理解,进而为预防和治疗干预提供信息。
研究设计与样本
- FPDMM自然史研究,2019年1月至2021年12月入组214名参与者,包括来自45个无关家庭的111名携带39种不同RUNX1变异的患者。
- 试验注册于www.clinicaltrials.gov,编号NCT03854318。
主要发现
- 77例患者中70例有血小板减少,18例中18例血小板聚集异常,35例中16例血小板致密颗粒减少,55例中28例出血评分异常。
- 55例非恶性骨髓中12例巨核细胞数量增加,42例巨核细胞发育异常,55例成人中30例及21例儿童中17例见细胞减少。
- 111例患者中19例诊断为血液系统恶性肿瘤,包括骨髓增生异常综合征、急性髓系白血病、慢性粒单核细胞白血病、急性淋巴细胞白血病和冒烟型骨髓瘤。
- 19例血液系统恶性肿瘤患者中18例对初始治疗耐药或复发并转诊行干细胞移植。
- 45个家庭中28个家庭至少有1名成员患血液系统恶性肿瘤;45例患者中42例有过敏症状,30例中24例有胃肠道症状。
局限性
- 这项研究正在持续入组,将进一步对更多FPDMM患者进行基因分型和表型分析,可能增进对疾病发病机制和临床病程的理解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Deleterious germ line RUNX1 variants cause the autosomal dominant familial platelet disorder with associated myeloid malignancy (FPDMM), characterized by thrombocytopenia, platelet dysfunction, and a predisposition to hematologic malignancies (HMs). We launched a FPDMM natural history study and, from January 2019 to December 2021, enrolled 214 participants, including 111 patients with 39 different RUNX1 variants from 45 unrelated families. Seventy of 77 patients had thrombocytopenia, 18 of 18 had abnormal platelet aggregometry, 16 of 35 had decreased platelet dense granules, and 28 of 55 had abnormal bleeding scores. Nonmalignant bone marrows showed increased numbers of megakaryocytes in 12 of 55 patients, dysmegakaryopoiesis in 42 of 55, and reduced cellularity for age in 30 of 55 adult and 17 of 21 pediatric cases. Of 111 patients, 19 were diagnosed with HMs, including myelodysplastic syndrome, acute myeloid leukemia, chronic myelomonocytic leukemia, acute lymphoblastic leukemia, and smoldering myeloma. Of those 19, 18 were relapsed or refractory to upfront therapy and referred for stem cell transplantation. In addition, 28 of 45 families had at least 1 member with HM. Moreover, 42 of 45 patients had allergic symptoms, and 24 of 30 had gastrointestinal (GI) symptoms. Our results highlight the importance of a multidisciplinary approach, early malignancy detection, and wider awareness of inherited disorders. This actively accruing, longitudinal study will genotype and phenotype more patients with FPDMM, which may lead to a better understanding of the disease pathogenesis and clinical course, which may then inform preventive and therapeutic interventions. This trial was registered at www.clinicaltrials.gov as #NCT03854318.
引用
- Cunningham L, Merguerian M, Calvo KR, et al. Natural history study of patients with familial platelet disorder with associated myeloid malignancy. Blood. 2023. PMID: 37738626. doi:10.1182/blood.2023019746
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。